The relationship between Chlamydia pneumonia Infection and Multiple Sclerosis

The mandatory intracellular bacterial infection Chlamydia pneumoniae has been extensively researched as a potential contributor to the onset or exacerbation of certain disorders. This obligate intracellular pathogen is being studied as a potential mediator of chronic inflammatory illnesses due to its unique lifestyle and ability to proliferate within the host while evading immune identification. From October 2023 to February 2024, 90 blood samples were obtained from patients aged 15 to 75 years. The consulting medical staff of Dr. Saad Al-Witry Hospital for Neurosciences rendered diagnosis for these patients. Three categories were created from the patient’s groups: In the first group, there were 14 patients with multiple sclerosis and C. pneumonia; in the second group, there were 46 patients with multiple sclerosis but no C. pneumonia; and in the third group, there were 30 people who are apparently healthy individuals. Using the Enzyme-Linked Immunosorbent Assay (ELISA) technique, the levels of interleukin-10 (IL-10), interleukin-6 (IL-6) and IgM and IgG antibodies against C. pneumonia were measured in each of the studied groups. When compared to the control group, the statistical analysis reveals a highly significant increase (P≤0.01) in anti- C. pneumonia IgM and anti- C. pneumonia IgG as well as interleukin-10 (IL-10) and interleukin-6 (IL-6) in the sera of MS patients with C. pneumonia comparing it to the control group, it also demonstrates a highly significant increase (P≤0.01) in MS diseases In conclusion, C. pneumonia may play a role as trigger factor of neurological disease such as multiple sclerosis